BRETARIS GENUAIR Inhalation powder Ref.[6076] Active ingredients: Aclidinium

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: Covis Pharma Europe B.V., Gustav Mahlerplein 2, 1082MA Amsterdam, The Netherlands

Product name and form

Bretaris Genuair 322 micrograms inhalation powder.

Pharmaceutical Form

Inhalation powder.

White or almost white powder in a white inhaler with an integral dose indicator and a green dosage button.

Qualitative and quantitative composition

Each delivered dose (the dose leaving the mouthpiece) contains 375 µg aclidinium bromide equivalent to 322 µg of aclidinium. This corresponds to a metered dose of 400 µg aclidinium bromide equivalent to 343 µg aclidinium.

Excipients with known effect: Each delivered dose contains approximately 12 mg lactose (as monohydrate).

For the full list of excipients, see section 6.1.

Active Ingredient Description
Aclidinium

Aclidinium is a competitive, selective muscarinic receptor antagonist (also known as an anticholinergic), with a longer residence time at the M3 receptors than the M2 receptors. M3 receptors mediate contraction of airway smooth muscle. Inhaled aclidinium acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.

List of Excipients

Lactose monohydrate

Pack sizes and marketing

The inhaler device is a multicomponent device made of polycarbonate, acrylonitrile-butadiene-styrene, polyoxymethylene, polyester-butylene-terephthalate, polypropylene, polystyrene and stainless steel. It is white-coloured with an integral dose indicator and a green dosage button. The mouthpiece is covered with a removable green protective cap. The inhaler is supplied in a plastic laminate pouch, placed in a cardboard carton.

Carton containing 1 inhaler with 30 doses.

Carton containing 1 inhaler with 60 doses.

Carton containing 3 inhalers each with 60 doses.

Not all pack sizes may be marketed.

Marketing authorization holder

Covis Pharma Europe B.V., Gustav Mahlerplein 2, 1082MA Amsterdam, The Netherlands

Marketing authorization dates and numbers

EU/1/12/781/001
EU/1/12/781/002
EU/1/12/781/003

Date of first authorisation: 20 July 2012
Date of last renewal: 20 April 2017

Drugs

Drug Countries
BRETARIS GENUAIR Austria, Australia, Estonia, Spain, Croatia, Ireland, Lithuania, Netherlands, New Zealand, Poland, Romania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.